Evidence map›Paper›PMID 35235711›Full record

ArticleClinical and translational science2022

Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.

Shuang Zhou, Ran Xie, Xiaodan Zhang, Xu He, Jie Huang, Yin Jungang, Man Liao, Ying Ding, Dandan Yang, Ying Liu and 11 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Shuang ZhouDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Ran XieDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Xiaodan ZhangDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Xu HeDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Jie HuangCenter for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yin JungangGCP Center, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Man LiaoHebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
Ying DingThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Dandan YangCenter of Clinical Pharmacology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ying LiuThe Office of Drug Clinical Trial Institution, Wuhan Jinyintan Hospitial, Wuhan, China.
Qian ZhangDepartment of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Guoping YangCenter for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fang LiuGCP Center, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Shengjiang GuanHebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
Qing HeThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Honggang LouCenter of Clinical Pharmacology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Fengyun GongThe Office of Drug Clinical Trial Institution, Wuhan Jinyintan Hospitial, Wuhan, China.
Xianmin MengDepartment of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qian XiangDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Xia ZhaoDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Yimin CuiDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Peking University First Hospital · CNCentral South University · CNJiangsu Province Hospital · CNJinyintan Hospital · CNPeking University · CNSecond Affiliated Hospital of Zhejiang University · CNShanghai Public Health Clinical Center · CNHebei University of Chinese Medicine · CNHospital of Hebei Province · CNNanjing Medical University · CNWuxi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics (PKs) of omeprazole in healthy Chinese volunteers. A 20 mg single dose of omeprazole (Losec) enteric-coated capsules or tablets was orally administered to 656 healthy subjects from eight subcenters. The polymorphic alleles of CYP2C19*2, *3, and *17 were determined by Sanger sequencing and Agena mass array. Plasma concentrations of omeprazole were determined by high-performance liquid-chromatography tandem mass spectrometry. PK parameters of area under the concentration versus time curve (AUC)

Indexed as

Anti-Ulcer AgentsCytochrome P-450 CYP2C19OmeprazoleArea Under CurveChinaGenotypeHumansAnti-Ulcer AgentsCYP2C19 protein, humanCytochrome P-450 CYP2C19OmeprazoleCYP2C19multicenter studyomeprazolepharmacokineticspolymorphisms

Identifiers

PMID35235711
PMCPMC9199891
OpenAlexW4214940000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.